Areas of Interest & Competitive Research Grants
Areas of Interest (AOI)
We are currently accepting concepts for the following therapeutic areas. BMS periodically opens RFP Cycles across different therapeutic areas and the pre-concept submission periods will be posted below when available. We strongly encourage all applicants to begin the online application process early to allow adequate time for completion. For a submission to qualify for review, all information including any required uploads must be submitted through the application form prior to the specified end dates for the RFP Cycle.
| Therapeutic Area and / or Compound | AOIs Posted on BMS.com | Pre-Concept Submission Period | |
| Start Date | End date | ||
| Immunology – Sotyktu (Deucravacitinib) | 27-Feb-23 | 03-Apr-23 | 04-May-23 |
| Immunology – Zeposia MS (Ozanimod) | 20-Mar-23 | 01-May-23 | 18-May-23 |
| Oncology – Repotrectinib (BMS-986472) | 06-Feb-23 | 10-Feb-23 | 17-Mar-23 |
Repotrectinib: Areas of Interest (AOI) in NSCLC
In Scope
- Studies to explore the efficacy and safety of repotrectinib in special populations of patients with ROS1+ metastatic NSCLC (e.g., poor Performance Status (PS), brain metastases, elderly).
- Studies to explore the efficacy and safety of repotrectinib (as monotherapy) in patients with metastatic NSCLC harboring ALK translocations or with other targetable driver genetic alterations where repotrectinib has preclinical activity.
- Studies to explore the efficacy and safety or repotrectinib (as monotherapy) in patients with ROS1+ NSCLC and resistance mutations; studies to characterize resistance mechanisms to repotrectinib (and potentially actionable targets to overcome resistance, including combination strategies).
Out Scope
- Combination with I-O agents.
- Alternative dosing and treatment schedules.
- Head-to-head studies versus current SOC.
- Studies in pediatric population (<18 y.o.).
Please note that during an open RFP submission window, clicking on a link to submit your research idea will take you to the FastTrack Investigator Portal and you will receive a message that you are leaving BMS.com. This is part of the normal process.
- If you are a potential investigator who is interested in seeking support to conduct independent research involving Nivolumab in Japan, Taiwan, or Korea, click here
- If you are a potential investigator who is interested in seeking support for independent research using Apixaban, click here.
- If you are a potential investigator who is interested in seeking support for non-clinical research using a BMS product, click here
- If you are a potential investigator who is interested in seeking support for independent research using one of our early pipeline assets, click here